Search

Your search keyword '"Caballero, Carmela"' showing total 151 results
Start Over Author "Caballero, Carmela"
151 results on '"Caballero, Carmela"'

2. Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

Author

Brandão, Mariana, Martins-Branco, Diogo, De Angelis, Claudia, Vuylsteke, Peter, Gelber, Richard D., Van Damme, Nancy, van Walle, Lien, Ferreira, Arlindo R., Lambertini, Matteo, Poggio, Francesca, Verhoeven, Didier, Barbeaux, Annelore, Duhoux, Francois P., Wildiers, Hans, Caballero, Carmela, Awada, Ahmad, Piccart-Gebhart, Martine, Punie, Kevin, and de Azambuja, Evandro

Published
2024
Full Text
View/download PDF

3. Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

Author

Brandão, Mariana, Martins-Branco, Diogo, De Angelis, Claudia, Vuylsteke, Peter, Gelber, Richard D., Van Damme, Nancy, van Walle, Lien, Ferreira, Arlindo R., Lambertini, Matteo, Poggio, Francesca, Verhoeven, Didier, Barbeaux, Annelore, Duhoux, Francois P., Wildiers, Hans, Caballero, Carmela, Awada, Ahmad, Piccart-Gebhart, Martine, Punie, Kevin, and de Azambuja, Evandro

Published
2024
Full Text
View/download PDF

6. Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.

Author

Loibl, Sibylle, Jassem, Jacek, Sonnenblick, Amir, Parlier, Damien, Winer, Eric, Bergh, Jonas, Gelber, Richard D., Restuccia, Eleonora, Im, Young-Hyuck, Huang, Chiun-Sheng, Dalenc, Florence, Calvo, Isabel, Procter, Marion, Caballero, Carmela, Clark, Emma, Raimbault, Alice, McConnell, Robin, Monturus, Estefania, de Azambuja, Evandro, and Gomez, Henry L.

Published
2024
Full Text
View/download PDF

8. Surgical quality assurance in head and neck cancer trials: an EORTC Head and Neck Cancer Group position paper based on the EORTC 1420 ‘Best of’ and 24954 ‘larynx preservation’ study

Author

Simon, Christian, Caballero, Carmela, Gregoire, Vincent, Thurnher, Dietmar, Koivunen, Petri, Ceruse, Philippe, Spriano, Giuseppe, Nicolai, Piero, Licitra, Lisa, Machiels, Jean-Pascal, Hamoir, Marc, Andry, Guy, Mehanna, Hisham, Hunter, Keith D., Dietz, Andreas, and René Leemans, C.

Published
2018
Full Text
View/download PDF

9. ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer

Author

Allum, William, Lordick, Florian, Alsina, Maria, Andritsch, Elisabeth, Ba-Ssalamah, Ahmed, Beishon, Marc, Braga, Marco, Caballero, Carmela, Carneiro, Fatima, Cassinello, Fernando, Dekker, Jan Willem, Delgado-Bolton, Roberto, Haustermans, Karin, Henning, Geoffrey, Hutter, Bettina, Lövey, József, Netíková, Irena Štenglová, Obermannová, Radka, Oberst, Simon, Rostoft, Siri, Saarto, Tiina, Seufferlein, Thomas, Sheth, Sapna, Wynter-Blyth, Venetia, Costa, Alberto, and Naredi, Peter

Published
2018
Full Text
View/download PDF

10. EORTC 1409 GITCG/ESSO 01 - A prospective colorectal liver metastasis database for borderline or initially unresectable diseases (CLIMB): Lessons learnt from real life. From paradigm to unmet need

Author

Collienne, Maike, primary, Neven, Anouk, additional, Caballero, Carmela, additional, Kataoka, Kozo, additional, Carrion-Alvarez, Lucia, additional, Nilsson, Henrik, additional, Désolneux, Grégoire, additional, Rivoire, Michel, additional, Ruers, Theo, additional, Gruenberger, Thomas, additional, Protic, Mladjan, additional, Troisi, Roberto Ivan, additional, Primavesi, Florian, additional, Staettner, Stefan, additional, Rahbari, Nuh, additional, Schnitzbauer, Andreas, additional, Malik, Hassan, additional, Swijnenburg, Rutger-Jan, additional, Mauer, Murielle, additional, Ducreux, Michel, additional, and Evrard, Serge, additional

Published
2023
Full Text
View/download PDF

11. Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

Author

Brandão, Mariana, primary, Martins-Branco, Diogo, additional, De Angelis, Claudia, additional, Vuylsteke, Peter, additional, Gelber, Richard D., additional, Van Damme, Nancy, additional, van Walle, Lien, additional, Ferreira, Arlindo R., additional, Lambertini, Matteo, additional, Poggio, Francesca, additional, Verhoeven, Didier, additional, Barbeaux, Annelore, additional, Duhoux, Francois P., additional, Wildiers, Hans, additional, Caballero, Carmela, additional, Awada, Ahmad, additional, Piccart-Gebhart, Martine, additional, Punie, Kevin, additional, and de Azambuja, Evandro, additional

Published
2023
Full Text
View/download PDF

15. Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)

Author

Moehler, Markus, Schad, Arno, Maderer, Annett, Atasoy, Ajlan, Mauer, Murielle E., Caballero, Carmela, Thomaidis, Thomas, John, Jestinah M. Mahachie, Lang, Istvan, Van Cutsem, Eric, Freire, João, Lutz, Manfred P., Roth, Arnaud, and the EORTC Gastrointestinal Tract Cancer Group

Published
2018
Full Text
View/download PDF

16. EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

Author

Wagner, Anna Dorothea, Grabsch, Heike I., Mauer, Murielle, Marreaud, Sandrine, Caballero, Carmela, Thuss-Patience, Peter, Mueller, Lothar, Elme, Annelie, Moehler, Markus Hermann, Martens, Uwe, Kang, Yoon-Koo, Rha, Sun Young, Cats, Annemieke, Tokunaga, Masanori, and Lordick, Florian

Published
2019
Full Text
View/download PDF

17. Supplementary file - liver genes from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

Author

Aftimos, Philippe, primary, Oliveira, Mafalda, primary, Irrthum, Alexandre, primary, Fumagalli, Debora, primary, Sotiriou, Christos, primary, Gal-Yam, Einav Nili, primary, Robson, Mark E., primary, Ndozeng, Justin, primary, Di Leo, Angelo, primary, Ciruelos, Eva M., primary, de Azambuja, Evandro, primary, Viale, Giuseppe, primary, Scheepers, Elsemieke D., primary, Curigliano, Giuseppe, primary, Bliss, Judith M., primary, Reis-Filho, Jorge S., primary, Colleoni, Marco, primary, Balic, Marija, primary, Cardoso, Fatima, primary, Albanell, Joan, primary, Duhem, Caroline, primary, Marreaud, Sandrine, primary, Romagnoli, Dario, primary, Rojas, Beatriz, primary, Gombos, Andrea, primary, Wildiers, Hans, primary, Guerrero-Zotano, Angel, primary, Hall, Peter, primary, Bonetti, Andrea, primary, Larsson, Karolina Fs, primary, Degiorgis, Martina, primary, Khodaverdi, Silvia, primary, Greil, Richard, primary, Sverrisdóttir, Ásgerdur, primary, Paoli, Marta, primary, Seyll, Ethel, primary, Loibl, Sibylle, primary, Linderholm, Barbro, primary, Zoppoli, Gabriele, primary, Davidson, Nancy E., primary, Johannsson, Oskar Th, primary, Bedard, Philippe L., primary, Loi, Sherene, primary, Knox, Susan, primary, Cameron, David A., primary, Harbeck, Nadia, primary, Montoya, Maite Lasa, primary, Brandão, Mariana, primary, Vingiani, Andrea, primary, Caballero, Carmela, primary, Hilbers, Florentine S., primary, Yates, Lucy R., primary, Benelli, Matteo, primary, Venet, David, primary, and Piccart, Martine J., primary

Published
2023
Full Text
View/download PDF

18. Data from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

Author

Aftimos, Philippe, primary, Oliveira, Mafalda, primary, Irrthum, Alexandre, primary, Fumagalli, Debora, primary, Sotiriou, Christos, primary, Gal-Yam, Einav Nili, primary, Robson, Mark E., primary, Ndozeng, Justin, primary, Di Leo, Angelo, primary, Ciruelos, Eva M., primary, de Azambuja, Evandro, primary, Viale, Giuseppe, primary, Scheepers, Elsemieke D., primary, Curigliano, Giuseppe, primary, Bliss, Judith M., primary, Reis-Filho, Jorge S., primary, Colleoni, Marco, primary, Balic, Marija, primary, Cardoso, Fatima, primary, Albanell, Joan, primary, Duhem, Caroline, primary, Marreaud, Sandrine, primary, Romagnoli, Dario, primary, Rojas, Beatriz, primary, Gombos, Andrea, primary, Wildiers, Hans, primary, Guerrero-Zotano, Angel, primary, Hall, Peter, primary, Bonetti, Andrea, primary, Larsson, Karolina Fs, primary, Degiorgis, Martina, primary, Khodaverdi, Silvia, primary, Greil, Richard, primary, Sverrisdóttir, Ásgerdur, primary, Paoli, Marta, primary, Seyll, Ethel, primary, Loibl, Sibylle, primary, Linderholm, Barbro, primary, Zoppoli, Gabriele, primary, Davidson, Nancy E., primary, Johannsson, Oskar Th, primary, Bedard, Philippe L., primary, Loi, Sherene, primary, Knox, Susan, primary, Cameron, David A., primary, Harbeck, Nadia, primary, Montoya, Maite Lasa, primary, Brandão, Mariana, primary, Vingiani, Andrea, primary, Caballero, Carmela, primary, Hilbers, Florentine S., primary, Yates, Lucy R., primary, Benelli, Matteo, primary, Venet, David, primary, and Piccart, Martine J., primary

Published
2023
Full Text
View/download PDF

19. Supplementary methods, tables and figures. from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

Author

Aftimos, Philippe, primary, Oliveira, Mafalda, primary, Irrthum, Alexandre, primary, Fumagalli, Debora, primary, Sotiriou, Christos, primary, Gal-Yam, Einav Nili, primary, Robson, Mark E., primary, Ndozeng, Justin, primary, Di Leo, Angelo, primary, Ciruelos, Eva M., primary, de Azambuja, Evandro, primary, Viale, Giuseppe, primary, Scheepers, Elsemieke D., primary, Curigliano, Giuseppe, primary, Bliss, Judith M., primary, Reis-Filho, Jorge S., primary, Colleoni, Marco, primary, Balic, Marija, primary, Cardoso, Fatima, primary, Albanell, Joan, primary, Duhem, Caroline, primary, Marreaud, Sandrine, primary, Romagnoli, Dario, primary, Rojas, Beatriz, primary, Gombos, Andrea, primary, Wildiers, Hans, primary, Guerrero-Zotano, Angel, primary, Hall, Peter, primary, Bonetti, Andrea, primary, Larsson, Karolina Fs, primary, Degiorgis, Martina, primary, Khodaverdi, Silvia, primary, Greil, Richard, primary, Sverrisdóttir, Ásgerdur, primary, Paoli, Marta, primary, Seyll, Ethel, primary, Loibl, Sibylle, primary, Linderholm, Barbro, primary, Zoppoli, Gabriele, primary, Davidson, Nancy E., primary, Johannsson, Oskar Th, primary, Bedard, Philippe L., primary, Loi, Sherene, primary, Knox, Susan, primary, Cameron, David A., primary, Harbeck, Nadia, primary, Montoya, Maite Lasa, primary, Brandão, Mariana, primary, Vingiani, Andrea, primary, Caballero, Carmela, primary, Hilbers, Florentine S., primary, Yates, Lucy R., primary, Benelli, Matteo, primary, Venet, David, primary, and Piccart, Martine J., primary

Published
2023
Full Text
View/download PDF

20. Abstract PD6-11: PD6-11 Evaluation of the Sensitivity to Endocrine Therapy Index (SET2,3) in Early Male Breast Cancer: Results from an analysis in the EORTC 10085/TBCRC/BIG/NCTN International Male Breast Cancer Program

Author

Zakon, Danielle B., primary, Poncet, Coralie, additional, Cardoso, Fatima, additional, Anouk, Neven, additional, Valero, Vicente, additional, Aebi, Stefan, additional, Benstead, Kim, additional, Bogler, Oliver, additional, Lago, Lissandra Dal, additional, Fraser, Judith, additional, Caballero, Carmela, additional, Hedenfalk, Ingrid A., additional, Korde, Larissa A., additional, Linderholm, Barbro, additional, Martens, John WM, additional, Middleton, Lavinia P., additional, Murray, Melissa, additional, Kelly, Catherine M., additional, Nilsson, Cecilia, additional, Nowaczyk, Monika, additional, Peeters, Stephanie, additional, Beauvois, Melanie, additional, Porter, Peggy, additional, Schroder, Carolien P., additional, Rubio, Isabel T., additional, Ruddy, Kathryn, additional, van Asperen, Christi, additional, Weyngaert, Danielle Van Den, additional, van Deurzen, Carolien HM, additional, van Leeuwen-Stok, Elise, additional, Vermeij, Joanna M., additional, Bartlett, John MS, additional, Wolff, Antonio C., additional, Giordano, Sharon H., additional, and Symmans, W. Fraser, additional

Published
2023
Full Text
View/download PDF

21. European Cancer Summit 2022 submission for Quality Cancer Care NetworkVariations in the definition and perceived importance of positive resection margins in patients with colorectal cancer: a survey study

Author

Smith, Henry G, primary, Schlesinger, Nis H, additional, Lundon, Dara, additional, Ben-Yaacov, Almog, additional, Caballero, Carmela, additional, Ceelen, Wim, additional, Suppan, Ina, additional, Kok, Johnn Herrera, additional, Holmberg, Carl, additional, Lorenzon, Laura, additional, Mohan, Helen, additional, Montagna, Giacomo, additional, Santrac, Nada, additional, Sayyed, Raza, additional, Schrage, Yvonne, additional, Sgarbura, Olivia, additional, Vasileva-Slaveva, Mariela, additional, and Brandl, Andreas, additional

Published
2023
Full Text
View/download PDF

22. The assessment and treatment strategies of malnutrition in patients with cancer treated by surgical oncologist – an EYSAC snapshot analysis

Author

Brandl, Andreas, primary, Lundon, Dara, additional, Lorenzon, Laura, additional, Schrage, Yvonne, additional, Caballero, Carmela, additional, Holmberg, Carl Jacob, additional, Santrac, Nada, additional, Vasileva-Slaveva, Mariela, additional, Montagna, Giacomo, additional, Mohan, Helen, additional, Sgarbura, Olivia, additional, Sayyed, Raza, additional, Ben-Yaacov, Almog, additional, Carriço, Marta, additional, Henry Hererra Kok, Johnn, additional, Smith, Henry G., additional, Suppan, Ina, additional, Sandrucci, Sergio, additional, and Ceelen, Wim, additional

Published
2023
Full Text
View/download PDF

24. Standards in surgical training in advanced pelvic malignancy across Europe and beyond – A Snapshot analysis

Author

Brandl, Andreas, primary, Lundon, Dara, additional, Lorenzon, Laura, additional, Schrage, Yvonne, additional, Caballero, Carmela, additional, Holmberg, Carl Jacob, additional, Santrac, Nada, additional, Vasileva-Slaveva, Mariela, additional, Montagna, Giacomo, additional, Sgarbura, Olivia, additional, Sayyed, Raza, additional, Ben-Yaacov, Almog, additional, Herrera Kok, Johnn Henry, additional, Suppan, Ina, additional, Mohan, Helen, additional, Kovacs, Tibor, additional, D'Ugo, Domenico, additional, Sandrucci, Sergio, additional, and Ceelen, Wim, additional

Published
2022
Full Text
View/download PDF

25. Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy

Author

Lambertini, Matteo, Fielding, Shona, Loibl, Sibylle, Janni, Wolfgang, Clark, Emma, Franzoi, Maria Alice, Fumagalli, Debora, Caballero, Carmela, Arecco, Luca, Salomoni, Sharon, Pondé, Noam, Poggio, Francesca, Kim, Hee Jeong, Villarreal-Garza, Cynthia, Pagani, Olivia, Paluch-Shimon, Shani, Ballestrero, Alberto, Del Mastro, Lucia, Piccart-Gebhart, Martine, Bines, Jose, Partridge, Ann A.H., de Azambuja, Evandro, Lambertini, Matteo, Fielding, Shona, Loibl, Sibylle, Janni, Wolfgang, Clark, Emma, Franzoi, Maria Alice, Fumagalli, Debora, Caballero, Carmela, Arecco, Luca, Salomoni, Sharon, Pondé, Noam, Poggio, Francesca, Kim, Hee Jeong, Villarreal-Garza, Cynthia, Pagani, Olivia, Paluch-Shimon, Shani, Ballestrero, Alberto, Del Mastro, Lucia, Piccart-Gebhart, Martine, Bines, Jose, Partridge, Ann A.H., and de Azambuja, Evandro

Abstract

Background: Young age at breast cancer (BC) diagnosis has historically been a rationale for overtreatment. Limited data with short follow-up exist on the prognostic value of age at diagnosis in HER2-positive BC and the benefit of anti-HER2 therapy in young patients. Methods: APHINITY (NCT01358877) is an international, placebo-controlled, double-blind randomized phase III trial in HER2-positive early BC patients investigating the addition of pertuzumab to adjuvant chemotherapy plus trastuzumab. The prognostic and predictive value of age on invasive disease-free survival (IDFS) as continuous and dichotomous variable (aged 40 years or younger and older than 40 years) was assessed. A subpopulation treatment effect pattern plot analysis was conducted to illustrate possible treatment-effect heterogeneity based on age as a continuous factor. Results: Of 4804 included patients, 768 (16.0%) were aged 40 years or younger at enrollment. Median follow-up was 74 (interquartile range = 62-75) months. Young age was not prognostic either as dichotomous (hazard ratio [HR] = 1.06, 95% confidence interval [CI] = 0.84 to 1.33) or continuous (HR = 1.00, 95% CI = 1.00 to 1.01) variable. Lack of prognostic effect of age was observed irrespective of hormone receptor status and treatment arm. No statistically significant interaction was observed between age and pertuzumab effect (Pinteraction = 0.61). Adding pertuzumab improved IDFS for patients in the young (HR = 0.86, 95% CI = 0.56 to 1.32) and older (HR = 0.75, 95% CI = 0.62 to 0.92) cohorts. Similar results were observed irrespective of hormone receptor status. Subpopulation treatment effect pattern plot analysis confirmed the benefit of pertuzumab in 6-year IDFS across age subpopulations. Conclusions: In patients with HER2-positive early BC treated with modern anticancer therapies, young age did not demonstrate either prognostic or predictive value, irrespective of hormone receptor status., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2022

26. Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy

Author

Lambertini, Matteo, primary, Fielding, Shona, additional, Loibl, Sibylle, additional, Janni, Wolfgang, additional, Clark, Emma, additional, Franzoi, Maria Alice, additional, Fumagalli, Debora, additional, Caballero, Carmela, additional, Arecco, Luca, additional, Salomoni, Sharon, additional, Ponde, Noam F, additional, Poggio, Francesca, additional, Kim, Hee Jeong, additional, Villarreal-Garza, Cynthia, additional, Pagani, Olivia, additional, Paluch-Shimon, Shani, additional, Ballestrero, Alberto, additional, Del Mastro, Lucia, additional, Piccart, Martine, additional, Bines, Jose, additional, Partridge, Ann H, additional, and de Azambuja, Evandro, additional

Published
2022
Full Text
View/download PDF

27. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

Author

Gelber, Richard D., primary, Wang, Xin V., additional, Cole, Bernard F., additional, Cameron, David, additional, Cardoso, Fatima, additional, Tjan-Heijnen, Vivianne, additional, Krop, Ian, additional, Loi, Sherene, additional, Salgado, Roberto, additional, Kiermaier, Astrid, additional, Frank, Elizabeth, additional, Fumagalli, Debora, additional, Caballero, Carmela, additional, de Azambuja, Evandro, additional, Procter, Marion, additional, Clark, Emma, additional, Restuccia, Eleonora, additional, Heeson, Sarah, additional, Bines, Jose, additional, Loibl, Sibylle, additional, and Piccart-Gebhart, Martine, additional

Published
2022
Full Text
View/download PDF

30. Abstract P2-13-42: Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial

Author

Lambertini, Matteo, primary, Fielding, Shona, additional, Loibl, Sibylle, additional, Janni, Wolfgang, additional, Clark, Emma, additional, Franzoi, Maria Alice, additional, Fumagalli, Debora, additional, Caballero, Carmela, additional, Arecco, Luca, additional, Salomoni, Sharon, additional, Ponde, Noam F, additional, Poggio, Francesca, additional, Kim, Hee Jeong, additional, Villarreal-Garza, Cynthia, additional, Pagani, Olivia, additional, Paluch-Shimon, Shani, additional, Ballestrero, Alberto, additional, Mastro, Lucia Del, additional, Piccart, Martine, additional, Bines, Jose, additional, Partridge, Ann H., additional, and de Azambuja, Evandro, additional

Published
2022
Full Text
View/download PDF

33. Training in advanced pelvic malignancy across Europe and beyond – an EYSAC snapshot analysis

Author

Brandl, Andreas, primary, Lundon, Dara, additional, Lorenzon, Laura, additional, Schrage, Yvonne, additional, Caballero, Carmela, additional, Holmberg, Carl Jacob, additional, Santrac, Nada, additional, Vasileva-Slaveva, Mariela, additional, Montagna, Giacomo, additional, Mohan, Helen, additional, Sgarbura, Olivia, additional, Sayyed, Raza, additional, Ben-Yaacov, Almog, additional, Hererra Kok, Johnny Henry, additional, Breinl, Ina, additional, Kovacs, Tibor, additional, D'Ugo, Domenico, additional, Sandrucci, Sergio, additional, and Ceelen, Wim, additional

Published
2022
Full Text
View/download PDF

35. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

Author

Aftimos, Philippe, primary, Oliveira, Mafalda, additional, Irrthum, Alexandre, additional, Fumagalli, Debora, additional, Sotiriou, Christos, additional, Gal-Yam, Einav Nili, additional, Robson, Mark E., additional, Ndozeng, Justin, additional, Di Leo, Angelo, additional, Ciruelos, Eva M., additional, de Azambuja, Evandro, additional, Viale, Giuseppe, additional, Scheepers, Elsemieke D., additional, Curigliano, Giuseppe, additional, Bliss, Judith M., additional, Reis-Filho, Jorge S., additional, Colleoni, Marco, additional, Balic, Marija, additional, Cardoso, Fatima, additional, Albanell, Joan, additional, Duhem, Caroline, additional, Marreaud, Sandrine, additional, Romagnoli, Dario, additional, Rojas, Beatriz, additional, Gombos, Andrea, additional, Wildiers, Hans, additional, Guerrero-Zotano, Angel, additional, Hall, Peter, additional, Bonetti, Andrea, additional, Larsson, Karolina Fs, additional, Degiorgis, Martina, additional, Khodaverdi, Silvia, additional, Greil, Richard, additional, Sverrisdóttir, Ásgerdur, additional, Paoli, Marta, additional, Seyll, Ethel, additional, Loibl, Sibylle, additional, Linderholm, Barbro, additional, Zoppoli, Gabriele, additional, Davidson, Nancy E., additional, Johannsson, Oskar Th, additional, Bedard, Philippe L., additional, Loi, Sherene, additional, Knox, Susan, additional, Cameron, David A., additional, Harbeck, Nadia, additional, Montoya, Maite Lasa, additional, Brandão, Mariana, additional, Vingiani, Andrea, additional, Caballero, Carmela, additional, Hilbers, Florentine S., additional, Yates, Lucy R., additional, Benelli, Matteo, additional, Venet, David, additional, and Piccart, Martine J., additional

Published
2021
Full Text
View/download PDF

36. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative.

Author

Aftimos, Philippe, Oliveira, Mafalda, Irrthum, Alexandre, Fumagalli, Debora, Sotiriou, Christos, Nili Gal-Yam, Einav, Robson, Mark ME, Ndozeng, Justin, Di Leo, Angelo, Ciruelos, Eva M, de Azambuja, Evandro, Viale, Giuseppe, Scheepers, Elsemieke D, Curigliano, Giuseppe, Bliss, Judith M, Reis-Filho, Jorge Sergio, Colleoni, Marco Angelo, Balic, Marija, Cardoso, Fatima, Albanell, Joan, Duhem, Caroline, Marreaud, Sandrine, Romagnoli, Dario, Rojas, Beatriz, Gombos, Andrea, Wildiers, Hans, Guerrero-Zotano, Angel, Hall, Peter, Bonetti, Andrea, Larsson, Karolina Fs, Degiorgis, Martina, Khodaverdi, Silvia, Greil, Richard, Sverrisdottir, Asgerdur, Paoli, Marta, Seyll, Ethel, Loibl, Sibylle, Linderholm, Barbro B.K., Zoppoli, Gabriele, Davidson, Nancy E, Johannsson, Oskar Th, Bedard, Philippe L, Loi, Sherene, Knox, Susan, Cameron, David A, Harbeck, Nadia, Lasa Montoya, Maite, Brandão, Mariana, Vingiani, Andrea, Caballero, Carmela, Hilbers, Florentine S, Yates, Lucy R, Benelli, Matteo, Venet, David, Piccart, Martine J, Aftimos, Philippe, Oliveira, Mafalda, Irrthum, Alexandre, Fumagalli, Debora, Sotiriou, Christos, Nili Gal-Yam, Einav, Robson, Mark ME, Ndozeng, Justin, Di Leo, Angelo, Ciruelos, Eva M, de Azambuja, Evandro, Viale, Giuseppe, Scheepers, Elsemieke D, Curigliano, Giuseppe, Bliss, Judith M, Reis-Filho, Jorge Sergio, Colleoni, Marco Angelo, Balic, Marija, Cardoso, Fatima, Albanell, Joan, Duhem, Caroline, Marreaud, Sandrine, Romagnoli, Dario, Rojas, Beatriz, Gombos, Andrea, Wildiers, Hans, Guerrero-Zotano, Angel, Hall, Peter, Bonetti, Andrea, Larsson, Karolina Fs, Degiorgis, Martina, Khodaverdi, Silvia, Greil, Richard, Sverrisdottir, Asgerdur, Paoli, Marta, Seyll, Ethel, Loibl, Sibylle, Linderholm, Barbro B.K., Zoppoli, Gabriele, Davidson, Nancy E, Johannsson, Oskar Th, Bedard, Philippe L, Loi, Sherene, Knox, Susan, Cameron, David A, Harbeck, Nadia, Lasa Montoya, Maite, Brandão, Mariana, Vingiani, Andrea, Caballero, Carmela, Hilbers, Florentine S, Yates, Lucy R, Benelli, Matteo, Venet, David, and Piccart, Martine J

Abstract

AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and metastasis pairs: 252 TGS, 152 RNA-Seq, 67 SNP Arrays), we found a driver role for GATA1 and MEN1 somatic mutations. Metastases were enriched in ESR1, PTEN, CDH1, PIK3CA and RB1 mutations; MDM4, MYC amplifications; ARID1A deletions. An increase in clonality was observed in driver genes like ERBB2 and RB1. Intrinsic subtype switching occurred in 36% of cases. Luminal A/B to HER2-Enriched switching was associated with TP53 and/or PIK3CA mutations. Metastases had lower immune score and increased immune permissive cells. High TMB correlated to shorter time to relapse in HR+/HER2- cancers. ESCAT tier I/II alterations were detected in 51% of patients and matched therapy was used in 7%. Integration of multi-omics analyses in clinical practice could impact treatment strategies in MBC., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2021

37. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial.

Author

de Azambuja, Evandro, primary, Eiger, Daniel, additional, Procter, Marion Jennifer, additional, Ponde, Noam Falbel, additional, Guillaume, Sebastien, additional, Parlier, Damien, additional, Lambertini, Matteo, additional, Desmet, Antoine, additional, Caballero, Carmela Aves, additional, Aguila, Christian, additional, Jerusalem, Guy Heinrich Maria, additional, Walshe, Janice Maria, additional, Frank, Elizabeth S., additional, Bines, Jose, additional, Loibl, Sibylle, additional, Piccart-Gebhart, Martine J., additional, Ewer, Michael S., additional, Dent, Susan Faye, additional, Plummer, Chris, additional, and Suter, Thomas M, additional

Published
2021
Full Text
View/download PDF

38. A multidisciplinary team and patient perspective on omission of surgery after neoadjuvant systemic therapy for early breast cancer: A European Society of Surgical Oncology (ESSO) Research Academy survey.

Author

Caballero, Carmela, Lundon, Dara J., Vasileva-Slaveva, Mariela, Montagna, Giacomo, Bonci, Eduard-Alexandru, Brandl, Andreas, Smith, Henry, Kok, Johnn Henry Herrera, Holmberg, Carl-Jacob, Sayyed, Raza, Santrac, Nada, Suppan, Ina, Kaul, Pallvi, Vassos, Nikolaos, Lorenzon, Laura, Murphy, Marlena, Ceelen, Wim, de Azambuja, Evandro, McIntosh, Stuart A., and Rubio, Isabel T.

Subjects
BREAST cancer surgery, PATIENT advocacy, PATIENTS' attitudes, ONCOLOGIC surgery, ALUMNI associations
Abstract

Surgical de-escalation aims to reduce morbidity without compromising oncological outcomes. Trials to de-escalate breast cancer (BC) surgery among exceptional responders after neoadjuvant systemic therapy (NST) are ongoing. Combined patient and clinician insights on this strategy are unknown. The European Society of Surgical Oncology Young Surgeons Alumni Club (EYSAC) performed an online survey to evaluate the perspective of multidisciplinary teams (MDTs) on omission of surgery ("no surgery") following complete response to NST for early BC. The aim was to identify MDT considerations and perceived barriers to omission of BC surgery. Patient insights were obtained through a focused group discussion (FGD) with four members of the patient advocacy group, Guiding Researchers and Advocates to Scientific Partnerships (GRASP). The MDT survey had 248 responses, with 229 included for analysis. Criteria for a "no surgery" approach included: patient's tumor and nodal status before (39.7 %) and after (45.9 %) NST and comorbidities (44.3 %). The majority chose standard surgery for hypothetical cases with a complete response to NST. Barriers for implementation were lack of definitive trials (55.9 %), "no surgery" not being discussed in MDTs (28.8 %) and lack of essential diagnostic or therapeutic options (24 %). Patients expressed communication gaps about BC surgery, lack of trust regarding accuracy of imaging, fear of regret and psychosocial burden of choosing less extensive surgery. Before accepting "no surgery" after complete response to NST, MDTs and patients need level 1 evidence from clinical trials, access to standard diagnostic modalities and treatments. Patient's fear of regretting less surgery need to be acknowledged and addressed. • Surgical de-escalation trials in primary breast cancer are ongoing. Some of these are investigating the efficacy and safety of completely omitting BC surgery among patients with exceptional response to NST at the early-stage setting. • The MDT and patient survey conducted by ESSO-EYSAC, showed that clinicians and patients have hesitation towards completely omitting BC surgery. Lack of definitive trials, the option to omit surgery not being discussed during MDT meetings and lack of essential diagnostic or therapeutic options, were barriers to safe omission of surgery. Patients expressed fear of regret, communication gaps about BC surgery and lack of trust in the accuracy of imaging as reasons for not being receptive to this strategy. • Further research is needed to personalize BC surgery. Well-designed clinical trials, access to recommended diagnostic and treatment options and informed decision making through evidence-based and patient-oriented communication to address fear of regretting less extensive surgery are needed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Abstract PS10-01: 6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A STEPP analysis of the APHINITY (BIG 4-11) trial

Author

Gelber, Richard D., primary, Wang, Xin Victoria, additional, Cole, Bernard F., additional, Cameron, David, additional, Cardoso, Fatima, additional, Tjan-Heijnen, Vivianne, additional, Krop, Ian, additional, Loi, Sherene, additional, Salgado, Roberto, additional, Kiermaier, Astrid, additional, Frank, Elizabeth, additional, Fumagalli, Debora, additional, Caballero, Carmela, additional, de Azambuja, Evandro, additional, Procter, Marion, additional, Clark, Emma, additional, Restuccia, Eleonora, additional, Heeson, Sarah, additional, Bines, Jose, additional, Loibl, Sibylle, additional, and Piccart-Gebhardt, Martine, additional

Published
2021
Full Text
View/download PDF

40. Abstract PD3-01: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial

Author

Krop, Ian, primary, Mittempergher, Lorenza, additional, Paulson, Joseph, additional, Andre, Fabrice, additional, Bonnefoi, Hervé, additional, Loi, Sherene, additional, Loibl, Sibylle, additional, Gelber, Richard D, additional, Caballero, Carmela, additional, Fumagalli, Debora, additional, Dreezen, Christa, additional, Bernards, Rene, additional, van ‘t Veer, Laura, additional, and Piccart, Martine, additional

Published
2021
Full Text
View/download PDF

43. Building a collaboration to improve surgical research through EORTC/ESSO 1409-CLIMB study: A prospective liver metastasis database with an integrated quality assurance program

Author

Caballero, Carmela, primary, Burock, Susen, additional, Carrion-Alvarez, Lucia, additional, Nilsson, Henrik, additional, Ruers, Theo, additional, Senellart, Perrine, additional, Rivoire, Michel, additional, Stattner, Stefan, additional, Primavesi, Florian, additional, Troisi, Roberto, additional, Gruenberger, Thomas, additional, Heil, Jan, additional, Schnitzbauer, Andreas A., additional, Rahbari, Nuh N., additional, Swijnenburg, Rutger-Jan, additional, Malik, Hassan, additional, Protic, Mladjan, additional, Kataoka, Kozo, additional, Mauer, Murielle, additional, Ducreux, Michel, additional, Poston, Graeme, additional, and Evrard, Serge, additional

Published
2019
Full Text
View/download PDF

45. Responding to the challenges of international collaborations between the east and the west - report of the first JCOG-EORTC symposium and a perspective from young JCOG and EORTC investigators

Author

Kataoka, Kozo, Kataoka, Kozo, Kaider-Person, Orit, Kasper, Bernd, Starlinger, Patrick, Caballero, Carmela, Menis, Jessica, Hendriks, Lizza E., Terada, Mitsumi, Collette, Laurence, Nakamura, Kenichi, Lacombe, Denis, Fukuda, Haruhiko, Kataoka, Kozo, Kataoka, Kozo, Kaider-Person, Orit, Kasper, Bernd, Starlinger, Patrick, Caballero, Carmela, Menis, Jessica, Hendriks, Lizza E., Terada, Mitsumi, Collette, Laurence, Nakamura, Kenichi, Lacombe, Denis, and Fukuda, Haruhiko

Abstract

International/intercontinental collaboration is necessary to set up new innovative clinical trials for cancer treatment. However, the infrastructure, especially Asia-Europe academic partnerships, to enable such collaboration has not been fully structured and differences and similarities between the research groups have not been well studied. In 2015, collaboration started between the biggest cancer research organizations in Asia and EU, Japan Clinical Oncology Group (JCOG) and European Organisation for Research and Treatment of Cancer (EORTC). Following the first pilot collaboration study, the first scientific symposium took place in December 2017 in Tokyo. Before the symposium, a working visit for EORTC investigators from the Early Career Investigator initiative (ECI), willing to develop projects within the JCOG-EORTC partnership, was held. In addition to the digest of the working visit and symposium, we aimed to describe the differences and similarities between the two groups and to identify key factors for collaboration from the perspective of the young investigators of the networks. These findings are described in this article.

Published
2019

47. Responding to the challenges of international collaborations between the east and the west – report of the first JCOG–EORTC symposium and a perspective from young JCOG and EORTC investigators

Author

Kataoka, Kozo, primary, Kaider-Person, Orit, additional, Kasper, Bernd, additional, Starlinger, Patrick, additional, Caballero, Carmela, additional, Menis, Jessica, additional, Hendriks, Lizza E, additional, Terada, Mitsumi, additional, Collette, Laurence, additional, Nakamura, Kenichi, additional, Lacombe, Denis, additional, and Fukuda, Haruhiko, additional

Published
2018
Full Text
View/download PDF

49. BEST OF: A phase III study assessing the best of radiotherapy (Intensity Modulated RadioTherapy, IMRT) compared to the best of surgery (Trans-Oral Surgery, TOS) in patients with T1-T2, N0 oropharyngeal squamous cell carcinoma (OPSCC).

Author

Simon, Christian, primary, Caballero, Carmela Aves, additional, Fortpied, Catherine, additional, Evans, Mererid, additional, Koivunen, Petri, additional, Stelmes, Jean-Jacques, additional, Urbanowicz, Maria, additional, Bourhis, Jean, additional, Zimmermann, Frank, additional, Klussmann, Jens Peter, additional, Dietz, Andreas, additional, Spriano, Giuseppe, additional, Leemans, C. Rene, additional, Singer, Susanne, additional, Tinhofer, Inge, additional, Patterson, Joanne, additional, Quaglini, Silvana, additional, Hunter, Keith, additional, and Gregoire, Vincent, additional

Published
2018
Full Text
View/download PDF

50. Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578).

Author

Locati, Laura, primary, Caballero, Carmela Aves, additional, Fortpied, Catherine, additional, Perrone, Federica, additional, Quattrone, Pasquale, additional, Harrington, Kevin, additional, Gregoire, Vincent, additional, and Licitra, Lisa F., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results